The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
In Science this week: environmental DNA can help in studies of marine animals, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.